Geoffrey Porges
PersonRelationship Network
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| N/A | N/A | Publication of physician survey by Geoffrey Porges. | N/A | View |
HOUSE_OVERSIGHT_025890.jpg
This document appears to be a printout of a news article or press release compilation regarding the FDA approval and market analysis of the Regeneron/Sanofi cholesterol drug, Praluent. It details financial projections, physician surveys, and quotes from executives at Regeneron, Sanofi, and CVS Caremark regarding pricing and accessibility. While the document bears a House Oversight stamp and mentions Donald Trump in a disconnected headline, the content focuses entirely on the pharmaceutical industry.
HOUSE_OVERSIGHT_026364.jpg
This article discusses the new cholesterol drug, Praluent, from Regeneron and Sanofi, focusing on its high price, which is 46% higher than analyst forecasts. It details the FDA's approval for a broader patient group than expected, the potential for wide prescription by doctors despite the label, and the expected resistance from insurance companies who will likely restrict its use. The article also includes commentary from executives at Regeneron and Sanofi, as well as analysts and cardiologists, on the drug's market potential and place alongside existing treatments like statins.
Physician survey on Praluent usage
A survey of physicians found that they would use Praluent in 30% to 40% of patients who had already had heart attacks. Doctors also expressed a preference for Praluent in the survey.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity